Teva Pharmaceuticals competitorsClear all

Teva Pharmaceuticals's top competitors include Viatris, WuXi AppTec, Merck, Novartis, Pfizer, AstraZeneca, Roche, Sanofi and Allergan.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Teva Pharmaceuticals
Teva Pharmaceuticals
Teva Pharmaceuticals is a global pharmaceutical company.
Viatris
Viatris
Viatris is a healthcare company.
WuXi AppTec
WuXi AppTec
WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies.
Merck
Merck
Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Roche
Roche
Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Allergan
Allergan
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
Founding Date
Founding Date
1901
Founding Date
2020
Founding Date
2000
Founding Date
1891
Founding Date
1996
Founding Date
1849
Founding Date
1999
Founding Date
1896
Founding Date
2004
Founding Date
1948
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Petah Tikva, IL HQ
Villa Adelina, AR
Macquarie Park, AU
Minsk, BY
Antwerpen, BE
São Paulo, BR
Dupnica, BG
see more
Locations
Canonsburg, US HQ
Carole Park, AU
Millers Point, AU
Sofia, BG
Toronto, CA
Beijing, CN
Beijing, CN
see more
Locations
Shanghai, CN HQ
Beijing, CN
Changzhou Shi, CN
Chengdu, CN
Nantong, CN
Shanghai, CN
Shanghai, CN
see more
Locations
Kenilworth, US HQ
Hydra, DZ
Munro, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
Manama, BH
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Melbourne, AU
Mulgrave, AU
Sydney, AU
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Wien, AT
see more
Locations
Paris, FR HQ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
Zaventem, BE
see more
Locations
Dublin, IE HQ
Buenos Aires, AR
Gordon, AU
Wien, AT
Machelen, BE
Guarulhos, BR
Sao Paulo, BR
see more
Employees
Employees
37,1007% decrease
Employees
45,000
Employees
27,272
Employees
71,0003% increase
Employees
105,7942% increase
Employees
88,3004% decrease
Employees
76,1008% increase
Employees
97,735
Employees
100,4094% decrease
Employees
17,4003% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
17 b
Valuation ($)
56.6 b
Valuation ($)
194.6 b
Valuation ($)
N/A
Valuation ($)
239.6 b
Valuation ($)
151 b
Valuation ($)
N/A
Valuation ($)
128.9 b
Valuation ($)
N/A
Twitter followers
Twitter followers
3.5 k
Twitter followers
1.8 k
Twitter followers
4.7 k
Twitter followers
210.5 k
Twitter followers
293.2 k
Twitter followers
26.7 k
Twitter followers
283.7 k
Twitter followers
232.6 k
Twitter followers
142.3 k
Twitter followers
4
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
29
Number of tweets (last 30 days)
26
Number of tweets (last 30 days)
20
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
41
Number of tweets (last 30 days)
31
Number of tweets (last 30 days)
16
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.1
Average likes per tweet (last 30 days)
1.1
Average likes per tweet (last 30 days)
13.7
Average likes per tweet (last 30 days)
10.8
Average likes per tweet (last 30 days)
27.7
Average likes per tweet (last 30 days)
40.8
Average likes per tweet (last 30 days)
9.6
Average likes per tweet (last 30 days)
20.2
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
73.08%
Percentage of tweets with engagement (last 30 days)
95%
Percentage of tweets with engagement (last 30 days)
40%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
90.32%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
398088
Alexa Website Rank
N/A
Alexa Website Rank
421511
Alexa Website Rank
56943
Alexa Website Rank
88970
Alexa Website Rank
28407
Alexa Website Rank
57766
Alexa Website Rank
48352
Alexa Website Rank
160471
Alexa Website Rank
286876
Employee Rating
Employee Rating
3.7
Employee Rating
3.4
Employee Rating
3.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
N/A
Employee Rating
3.3
Employee Rating
4

Financial

Revenue (est.)
Revenue (est.)
$16.7b (FY, 2020)
Revenue (est.)
$11.8b (FY, 2020)
Revenue (est.)
¥16.5b (FY, 2020)
Revenue (est.)
$48b (FY, 2020)
Revenue (est.)
$48.7b (FY, 2020)
Revenue (est.)
$41.9b (FY, 2020)
Revenue (est.)
$24.4b (FY, 2019)
Revenue (est.)
CHF63.8b (FY, 2019)
Revenue (est.)
€36b (FY, 2020)
Revenue (est.)
$16.1b (FY, 2019)
Cost of goods
Cost of goods
$8.9b (FY, 2020)
Cost of goods
$8.1b (FY, 2020)
Cost of goods
¥10.3b (FY, 2020)
Cost of goods
$15.5b (FY, 2020)
Cost of goods
$15.1b (FY, 2020)
Cost of goods
$8.7b (FY, 2020)
Cost of goods
$4.9b (FY, 2019)
Cost of goods
CHF18.4b (FY, 2019)
Cost of goods
€12.2b (FY, 2020)
Cost of goods
$2.5b (FY, 2019)
Gross profit
Gross profit
$7.7b (FY, 2020)
Gross profit
$3.7b (FY, 2020)
Gross profit
¥6.3b (FY, 2020)
Gross profit
$32.5b (FY, 2020)
Gross profit
$33.5b (FY, 2020)
Gross profit
$33.2b (FY, 2020)
Gross profit
$19.5b (FY, 2019)
Gross profit
CHF45.4b (FY, 2019)
Gross profit
€25.2b (FY, 2020)
Gross profit
$13.6b (FY, 2019)
Net income
Net income
($4.1b) (FY, 2020)
Net income
($669.9m) (FY, 2020)
Net income
¥3b (FY, 2020)
Net income
$7.1b (FY, 2020)
Net income
$8.1b (FY, 2020)
Net income
$9.7b (FY, 2020)
Net income
$1.2b (FY, 2019)
Net income
CHF14.1b (FY, 2019)
Net income
€12.4b (FY, 2020)
Net income
($5.1b) (FY, 2019)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
125 (FY, 2019)
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
100 (Q1, 2020)
Facilities
Facilities
90 (FY, 2019)
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
21 (FY, 2019)
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
15 (Dec, 2020)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
13 (FY, 2019)
Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
49 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Patients Included in Clinical Trials
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
33 k (FY, 2017)
Patients Included in Clinical Trials
282.5 k (FY, 2019)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
43 (Dec, 2020)
Phase I Trials Products (Oncology)
12 (FY, 2020)
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
32 (Nov, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
37 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
7 (Dec, 2020)
Phase II Trials Products (Oncology)
6 (FY, 2020)
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
25 (Nov, 2020)
Phase III Trials Products
44 (Q4, 2020)
Phase III Trials Products
23 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Neuroscience)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
2 (Dec, 2020)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
1 (FY, 2019)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
22 (Q4, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
26 (Dec, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
10 (May, 2018)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
171 (FY, 2020)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
N/A
Registration Phase Products
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
5 (Q4, 2020)
Registration Phase Products
9 (FY, 2019)
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
4 (FY, 2019)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
$ 358m
Total funding raised
N/A
Total funding raised
$ 902.6m
Total funding raised
$ 5.6m
Total funding raised
$ 6.5m
Total funding raised
N/A
Total funding raised
$ 1b
Total funding raised
$ 2.8b
Total funding raised
$ 310m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Viatris
HQ
Canonsburg, US
Employees
45,000

Viatris is a healthcare company.

View company
WuXi AppTec
HQ
Shanghai, CN
Employees
27,272

WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies.

View company
Merck
HQ
Kenilworth, US
Employees
71,000↑ 3% increase

Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals.

View company
Novartis
HQ
Basel, CH
Employees
105,794↑ 2% increase

Novartis is a company that researches, develops, manufactures, and markets healthcare products.

View company